@xconomy.com 6 days ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com 2 months ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com 2 months ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com 4 months ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 4 months ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com 5 months ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com 5 months ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com 6 months ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com 9 months ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com 10 months ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com 10 months ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com 1 year ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com 1 year ago
Acelity Sells to 3M in Deal Valued at $6.7 Billion, Ending IPO Plan
@xconomy.com 1 year ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com 1 year ago
Synthorx Files for IPO to Advance Enhanced Cytokine Drugs
@xconomy.com 1 year ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com 1 year ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@techcrunch.com 1 year ago
Public shareholders got high today on Tilray, the first marijuana company to IPO on Nasdaq
@xconomy.com 2 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M